Glaucoma presents a significant global health concern and affects millions of individuals worldwide and predicted a high increase in prevalence of about 111 million by 2040. The current standard treatment involves hypotensive eye drops; however, challenges such as patient adherence and limited drug bioavailability hinder the treatment effectiveness. Nanopharmaceuticals or nanomedicines offer promising solutions to overcome these obstacles. In this manuscript, we summarized the current limitations of conventional antiglaucoma treatment, role of nanomedicine in glaucoma treatment, rational design, factors effecting the performance of nanomedicine and different types of nanocarriers in designing of nanomedicine along with their applications in glaucoma treatment from recent literature. Current clinical challenges that hinder real-time application of antiglaucoma nanomedicine are highlighted. Lastly, future directions are identified for improving the therapeutic potential and translation of antiglaucoma nanomedicine into clinic.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409099 | PMC |
| http://dx.doi.org/10.1016/j.mtbio.2024.101229 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravitreal Sustained Release Steroid Implants Are Safe and Effective in Patients With Glaucoma Drainage Devices.
Retina
January 2025
Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Purpose: To describe effects of sustained-release steroid delivery devices on intraocular pressure (IOP) in eyes with glaucoma drainage devices (GDD).
Methods: Retrospective case series of eyes with steroid implants (dexamethasone or fluocinolone acetonide) and prior GDD (Ahmed, Baerveldt) without uveitis. Outcomes included IOP, IOP rise, central foveal thickness (CFT), and IOP medications.
Presumed Sympathetic Ophthalmia After Diode Laser Cyclophotocoagulation for Neovascular Glaucoma: A Case Series.
Ocul Immunol Inflamm
January 2025
Ophthalmology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Purpose: To describe a case series of presumed Sympathetic Ophthalmia (SO) triggered by diode laser cyclophotocoagulation (CPC) for the treatment of neovascular glaucoma.
Methods: Patients developing bilateral granulomatous uveitis after CPC between 2014 and 2024. Cases with prior ocular trauma or penetrating ocular surgery were excluded.
Coats disease presenting with vitreous hemorrhage and neovascular glaucoma.
Am J Ophthalmol Case Rep
March 2025
Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, 60612, USA.
Purpose: To describe a patient with Coats disease with an atypical presentation of neovascular glaucoma and vitreous hemorrhage.
Observations: A 15-year-old male presented with five days of pain, redness, and swelling and was found to have neovascular glaucoma in his right eye. Further evaluation revealed Coats disease stage 3AI with a subtotal exudative retinal detachment inferiorly, telangiectatic vessels, and vitreous hemorrhage.
Potential Functions and Causal Associations of GNLY in Primary Open-Angle Glaucoma: Integration of Blood-Derived Proteome, Transcriptome, and Experimental Verification.
J Inflamm Res
January 2025
Department of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Purpose: Genome-wide association studies (GWAS) have identified multiple genetic loci associated with primary open-angle glaucoma (POAG). However, the mechanisms by which these loci contribute to POAG progression remain unclear. This study aimed to identify potential causative genes involved in the development of POAG.
View Article and Find Full Text PDFVisually significant ocular decompression retinopathy following laser peripheral iridotomy in a patient with primary acute angle-closure glaucoma.
Am J Ophthalmol Case Rep
December 2024
Department of Ophthalmology, Ross Eye Institute, University at Buffalo, 1176 Main Street, Buffalo, NY, 14209, United States.
Purpose: We report a single case of ocular decompression retinopathy (ODR) following neodymium-doped yttrium aluminum garnet laser peripheral iridotomy (Nd:YAG LPI) for primary acute angle-closure glaucoma associated with delayed visual recovery secondary to optic nerve head edema and macular thickening.
Observations: A 56-year-old female patient presented to the emergency department with primary acute angle-closure glaucoma. After topical and IV therapy did not improve intraocular pressure (IOP), an Nd:YAG LPI was performed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!